Cytokinetics (CYTK) Treasury Shares (2011 - 2025)
Cytokinetics (CYTK) posted quarterly Treasury Shares of $2.6 million for Q4 2025, up 38.02% year-over-year from $1.9 million in Q4 2024, and up 38.02% quarter-over-quarter from $1.9 million in Q4 2024.
Cytokinetics (CYTK) Treasury Shares (2011 - 2025) Analysis & Trends
Cytokinetics (CYTK) has reported Treasury Shares for 15 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Treasury Shares rose 38.02% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (up 38.02% YoY), while the FY2025 annual figure was $2.6 million, up 38.02% from the prior year.
- Treasury Shares advanced to $2.6 million in Q4 2025 per CYTK's latest filing, from $1.9 million in the prior quarter.
- Across five years, Treasury Shares topped out at $2.6 million in Q4 2025 and bottomed at $1.2 million in Q4 2022.
- Historically, Treasury Shares has averaged $1.7 million across 5 years, with a median of $1.4 million in 2021.
- Annual changes were most pronounced in 2022 — Treasury Shares declined 14.18% — and 2025, when it jumped 38.02%.
- Cytokinetics' Treasury Shares stood at $1.4 million in 2021, then slipped by 14.18% to $1.2 million in 2022, then climbed by 13.21% to $1.4 million in 2023, then jumped by 35.68% to $1.9 million in 2024, then jumped by 38.02% to $2.6 million in 2025.
- Business Quant data shows CYTK's Treasury Shares at $2.6 million in Q4 2025, $1.9 million in Q4 2024, and $1.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.57 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 1.41 Mn |
| Dec 31, 2021 | 1.41 Mn |
| Dec 31, 2020 | 1.12 Mn |
| Dec 31, 2020 | 1.12 Mn |
| Dec 31, 2019 | 839,075.00 |
| Dec 31, 2019 | 839,075.00 |
| Dec 31, 2018 | 546,500.00 |
| Dec 31, 2018 | 546,500.00 |
| Mar 31, 2018 | 171,250.00 |
| Mar 31, 2018 | 171,250.00 |
| Dec 31, 2017 | 456,752.00 |
| Dec 31, 2017 | 456,752.00 |